PE20020760A1 - Derivados de pirimidina como antagonistas del receptor de neuroquinina 1 (nk-1) - Google Patents
Derivados de pirimidina como antagonistas del receptor de neuroquinina 1 (nk-1)Info
- Publication number
- PE20020760A1 PE20020760A1 PE2001001154A PE2001001154A PE20020760A1 PE 20020760 A1 PE20020760 A1 PE 20020760A1 PE 2001001154 A PE2001001154 A PE 2001001154A PE 2001001154 A PE2001001154 A PE 2001001154A PE 20020760 A1 PE20020760 A1 PE 20020760A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- neuroquinin
- antagonists
- receptor
- alcoxyl
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 3
- ADTNSTHKMIPKIJ-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-n-methylmethanamine Chemical compound CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ADTNSTHKMIPKIJ-UHFFFAOYSA-N 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- -1 PYRIMIDINYL Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE PIRIMIDINA DE FORMULA I DONDE R1 ES ALQUILO, ALCOXILO, PIRIDINILO, PIRIMIDINILO, FENILO, ENTRE OTROS; R2 ES H, ALQUILO, ALCOXILO, HALOGENO, TRIFLUOROMETILO; R3/R3' SON INDEPENDIENTE UNO DEL OTRO, H, ALQUILO; R4 ES HALO, TRIFLUOROMETILO, ALCOXILO; R5 ES H, ALQUILO; R ES INDEPENDIENTE UNO DEL OTRO H, ALQUILO; X ES -C(O)N(R)-, -N(R)C(O)-; Y ES O, S, SO2, -N(R)-; n ES 1-4; m ES 0-2. SON COMPUESTOS PREFERIDOS ACIDO 2-(4-METIL-PIPERAZIN-1-IL)-4-o-TOLILOXI-PIRIMIDIN-5-CARBOXILICO(3,5-BISTRIFLUOROMETIL-BENCIL)-METIL-AMIDA, ACIDO 2-PIPERAZIN-1-IL-4-o-TOLILOXI-PIRIMIDIN-5-CARBOXILICO(3,5-BISTRIFLUOROMETIL-BENCIL)-METIL-AMIDA, ACIDO 4-(2-CLORO-FENOXI)-2-(4-METIL-PIPERAZIN-1-IL)-PIRIMIDIN-5-CARBOXILICO(3,5-BISTRIFLUOROMETIL-BENCIL)-METIL-AMIDA. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR DE NEUROQUININA 1 (NK-1) Y SON UTILES PARA EL TRATAMIENTO DE MIGRANA, ARTRITIS, REUMATOIDE, ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00125529 | 2000-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020760A1 true PE20020760A1 (es) | 2002-08-21 |
Family
ID=8170446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001154A PE20020760A1 (es) | 2000-11-22 | 2001-11-19 | Derivados de pirimidina como antagonistas del receptor de neuroquinina 1 (nk-1) |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6787539B2 (es) |
| EP (1) | EP1339698A2 (es) |
| JP (1) | JP3993100B2 (es) |
| KR (1) | KR100571337B1 (es) |
| CN (1) | CN1309710C (es) |
| AR (1) | AR031486A1 (es) |
| AU (2) | AU2002227921B2 (es) |
| BG (1) | BG107840A (es) |
| BR (1) | BR0115480A (es) |
| CA (1) | CA2429570A1 (es) |
| CZ (1) | CZ20031666A3 (es) |
| EC (1) | ECSP034619A (es) |
| GT (1) | GT200100232A (es) |
| HR (1) | HRP20030362A2 (es) |
| HU (1) | HUP0303045A3 (es) |
| IL (2) | IL155705A0 (es) |
| JO (1) | JO2307B1 (es) |
| MA (1) | MA26967A1 (es) |
| MX (1) | MXPA03004453A (es) |
| NO (1) | NO324865B1 (es) |
| NZ (1) | NZ525555A (es) |
| PA (1) | PA8533501A1 (es) |
| PE (1) | PE20020760A1 (es) |
| PL (1) | PL366394A1 (es) |
| RU (1) | RU2284997C2 (es) |
| SK (1) | SK7612003A3 (es) |
| UY (1) | UY27034A1 (es) |
| WO (1) | WO2002042280A2 (es) |
| YU (1) | YU39503A (es) |
| ZA (1) | ZA200303517B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200402292T4 (tr) * | 2000-01-31 | 2004-12-21 | Pfizer Products Inc. | PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler. |
| US8455489B2 (en) * | 2003-11-10 | 2013-06-04 | Exelixis, Inc. | Substituted pyrimidine compositions and methods of use |
| JP4501015B2 (ja) | 2004-03-17 | 2010-07-14 | 味の素株式会社 | アミノピリミジン化合物の製造方法 |
| JP4613501B2 (ja) | 2004-03-17 | 2011-01-19 | 味の素株式会社 | ５−保護アミノピリミジン化合物の製造方法 |
| US7280223B2 (en) * | 2004-04-22 | 2007-10-09 | Zygo Corporation | Interferometry systems and methods of using interferometry systems |
| TW200608976A (en) | 2004-05-08 | 2006-03-16 | Neurogen Corp | 4,5-disubstituted-2-aryl pyrimidines |
| BRPI0606187A2 (pt) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada |
| DE102005027150A1 (de) * | 2005-03-12 | 2006-09-28 | Bayer Healthcare Ag | Pyrimidincarbonsäure-Derivate und ihre Verwendung |
| RU2279426C1 (ru) * | 2005-03-15 | 2006-07-10 | Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) | СПОСОБ ПОЛУЧЕНИЯ 2-(n-(1-АДАМАНТИЛ)ТИО)-4-(1-АДАМАНТИЛ)ОКСИ)-6-МЕТИЛПИРИМИДИНА |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| KR101032186B1 (ko) * | 2008-12-31 | 2011-05-02 | 엘에스산전 주식회사 | 정격 미세 조정이 가능한 과전류 계전기 |
| BR112012010220A2 (pt) * | 2009-10-30 | 2021-02-23 | Janssen Pharmaceutical N.V. | piridinas fenóxi-substituídas como modulares do receptor opioide |
| RU2568434C2 (ru) * | 2009-10-30 | 2015-11-20 | Янссен Фармацевтика Нв | Пиримидиновые соединения для использования в качестве модуляторов дельта-опиоидных рецепторов |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57131771A (en) * | 1981-02-10 | 1982-08-14 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
| FR2536071B1 (fr) * | 1982-11-12 | 1986-07-11 | Sanofi Sa | Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant |
| US4959368A (en) | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ATE364606T1 (de) | 1993-12-29 | 2007-07-15 | Merck Sharp & Dohme | Substituierte morpholinderivate und ihre verwendung als arzneimittel |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5734081A (en) * | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| TR200402292T4 (tr) * | 2000-01-31 | 2004-12-21 | Pfizer Products Inc. | PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler. |
-
2000
- 2000-11-13 YU YU39503A patent/YU39503A/sh unknown
-
2001
- 2001-10-15 US US09/977,586 patent/US6787539B2/en not_active Expired - Fee Related
- 2001-11-13 MX MXPA03004453A patent/MXPA03004453A/es active IP Right Grant
- 2001-11-13 RU RU2003117481/04A patent/RU2284997C2/ru not_active IP Right Cessation
- 2001-11-13 CZ CZ20031666A patent/CZ20031666A3/cs unknown
- 2001-11-13 JP JP2002544415A patent/JP3993100B2/ja not_active Expired - Fee Related
- 2001-11-13 WO PCT/EP2001/013084 patent/WO2002042280A2/en not_active Ceased
- 2001-11-13 KR KR1020037006777A patent/KR100571337B1/ko not_active Expired - Fee Related
- 2001-11-13 HU HU0303045A patent/HUP0303045A3/hu unknown
- 2001-11-13 AU AU2002227921A patent/AU2002227921B2/en not_active Ceased
- 2001-11-13 SK SK761-2003A patent/SK7612003A3/sk unknown
- 2001-11-13 HR HR20030362A patent/HRP20030362A2/xx not_active Application Discontinuation
- 2001-11-13 AU AU2792102A patent/AU2792102A/xx active Pending
- 2001-11-13 CA CA002429570A patent/CA2429570A1/en not_active Abandoned
- 2001-11-13 PL PL01366394A patent/PL366394A1/xx not_active Application Discontinuation
- 2001-11-13 CN CNB018191169A patent/CN1309710C/zh not_active Expired - Fee Related
- 2001-11-13 NZ NZ525555A patent/NZ525555A/en unknown
- 2001-11-13 BR BR0115480-0A patent/BR0115480A/pt not_active Application Discontinuation
- 2001-11-13 IL IL15570501A patent/IL155705A0/xx active IP Right Grant
- 2001-11-13 EP EP01989463A patent/EP1339698A2/en not_active Withdrawn
- 2001-11-15 JO JO2001188A patent/JO2307B1/en active
- 2001-11-19 PE PE2001001154A patent/PE20020760A1/es not_active Application Discontinuation
- 2001-11-21 PA PA20018533501A patent/PA8533501A1/es unknown
- 2001-11-21 AR ARP010105423A patent/AR031486A1/es not_active Application Discontinuation
- 2001-11-21 UY UY27034A patent/UY27034A1/es not_active Application Discontinuation
- 2001-11-21 GT GT200100232A patent/GT200100232A/es unknown
-
2003
- 2003-05-01 IL IL155705A patent/IL155705A/en not_active IP Right Cessation
- 2003-05-07 ZA ZA200303517A patent/ZA200303517B/en unknown
- 2003-05-21 EC EC2003004619A patent/ECSP034619A/es unknown
- 2003-05-21 NO NO20032291A patent/NO324865B1/no unknown
- 2003-05-22 BG BG107840A patent/BG107840A/bg unknown
- 2003-05-22 MA MA27173A patent/MA26967A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020760A1 (es) | Derivados de pirimidina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| DK1873148T3 (da) | Farmaceutiske sammensætninger, der indeholder krystallinske salte af 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-ensyre | |
| PE20011287A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina | |
| PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
| FI964815A0 (fi) | Piperatsiinijohdoksia 5-HT1A antagonisteina | |
| PE20010203A1 (es) | Derivados de 5-fenil-pirimidina como antagonistas del receptor de la neuroquinina 1 | |
| PT77735B (fr) | Procede de preparation de derives de benzoxazolinone | |
| PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
| DK163288D0 (da) | 2-(4-(4-(4-((2-(2,4-difluorphenyl)-2-(1h-azolylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)triazoloner | |
| PE20020603A1 (es) | Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy) | |
| PE20010153A1 (es) | Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina | |
| PE20030719A1 (es) | Derivados de 8-[bis(2-halofenil)metil]-3-heteroaril-8-azabiciclo[3.2.1] octan-3-ol como agonistas del receptor de nociceptina orl-1 | |
| ATE402151T1 (de) | 2-(arylphenyl)amino-imidazolin-derivate | |
| DK478788D0 (da) | Polymorf modifikation af forbindelsen 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-8-azaspiro-(4.5) decan-7,9-dion | |
| PE20030276A1 (es) | 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluor-2-metil)substituido)fenil-piridin-3-il]-n-metil-isobutiramida | |
| YU64901A (sh) | Derivati bifenila | |
| DK0573464T3 (da) | Fremgangsmåde til fremstilling af trans-piperidin-2,5-dicarboxylater | |
| DE69002340D1 (de) | Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung. | |
| NZ240298A (en) | 4-(4- and/or 6-(trifluoromethyl)pyrid-2-)piperazin-1-ylalkyl substituted lactam derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |